Why the study?
Recent clinical trials showed conflicting findings regarding the benefit of surgical revascularization added to optimal medical therapy and the utility of myocardial viability testing in left ventricular dysfunction.
Does surgical myocardial revascularization improve survival in patients with left ventricular dysfunction and coronary artery disease?
Does surgical myocardial revascularization improve survival in patients with left ventricular dysfunction and coronary artery disease?
Answers are grounded in this paper and cite their sources.
Surgical myocardial revascularization provides long-term mortality benefits in patients with ischemic left ventricular dysfunction, although routine myocardial viability testing may not accurately predict which patients will benefit.
No abstract yet. The journal hasn't published one we can show.
No takes yet. Share an insight, caveat, or question.
Armando Godoy-Palomino (2021) conducted a review in Ischemic cardiomyopathy / Left ventricular dysfunction (n=2,136). Coronary artery bypass grafting (CABG) plus optimal medical therapy vs. Optimal medical therapy alone was evaluated on All-cause mortality (HR 0.84, 95% CI 0.73-0.97, p=0.02).
Synapse has enriched 10 related papers. Consider them for comparative context: